MiMedx Group (MDXG) Stock Price, News & Analysis

Company Overview

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Key Stats

• Today's Range: $7.84 to $8.05
• 50-Day Range: $7.85 to $9.62
• 52-Week Range: $5.47 to $10.14
• Volume: 607,700 shs
• Average Volume: 488,266 shs
• Market Capitalization: $1.17 billion
• P/E Ratio: 14.51
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Buy

MiMedx Group Stock Analysis - MarketRank™

MiMedx Group scored higher than 63% of companies evaluated by MarketBeat, and ranked 404th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

MiMedx Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

MiMedx Group has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 6.67%

Earnings Growth

Earnings for MiMedx Group are expected to grow by 6.67% in the coming year, from $0.30 to $0.32 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MiMedx Group is 14.51, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.43.

Price to Earnings Ratio vs. Sector

The P/E ratio of MiMedx Group is 14.51, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.04.

Price to Book Value per Share Ratio

MiMedx Group has a P/B Ratio of 8.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.63% of the outstanding shares of MiMedx Group have been sold short.

Short Interest Ratio / Days to Cover

MiMedx Group has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in MiMedx Group has recently decreased by 13.23%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MiMedx Group does not currently pay a dividend.

Dividend Growth

MiMedx Group does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.63% of the outstanding shares of MiMedx Group have been sold short.

Short Interest Ratio / Days to Cover

MiMedx Group has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in MiMedx Group has recently decreased by 13.23%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for MiMedx Group this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for MDXG on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

4 people have added MiMedx Group to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MiMedx Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.30% of the stock of MiMedx Group is held by insiders.

Percentage Held by Institutions

79.15% of the stock of MiMedx Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MDXG Stock Analysis - Frequently Asked Questions

How have MDXG shares performed this year?

MiMedx Group's stock was trading at $9.62 at the start of the year. Since then, MDXG stock has decreased by 17.0% and is now trading at $7.98.
View the best growth stocks for 2025 here.

How were MiMedx Group's earnings last quarter?

MiMedx Group, Inc. (NASDAQ:MDXG) posted its quarterly earnings data on Wednesday, October, 30th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.02. The company had revenue of $84.06 million for the quarter, compared to the consensus estimate of $81 million. MiMedx Group had a net margin of 23.86% and a trailing twelve-month return on equity of 26.21%.

Who are MiMedx Group's major shareholders?

Top institutional investors of MiMedx Group include Trigran Investments Inc. (5.19%), Vanguard Group Inc. (4.56%), Paradigm Capital Management Inc. NY (3.19%) and Cannell Capital LLC (2.48%). Insiders that own company stock include Timothy R Wright, William Frank Iv Hulse, Rohit Kashyap, Robert Benjamin Stein, Scott M Turner, William Lawrence Phelan and Mark Graves.
View institutional ownership trends.

How do I buy shares of MiMedx Group?

Shares of MDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MiMedx Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MiMedx Group investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Hawkins (HWKN), Adobe (ADBE) and General Electric (GE).

Company Calendar

• Last Earnings: 10/30/2024
• Today: 2/22/2025
• Next Earnings (Estimated): 4/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:MDXG
• CUSIP: N/A
• CIK: 1376339
• Web: www.mimedx.com
• Phone: (770) 651-9100
• Fax: 678-384-6741
• Employees: 870
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $12.00
• High Stock Price Target: $14.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +50.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.55
• Trailing P/E Ratio: 14.51
• Forward P/E Ratio: 26.60
• P/E Growth: N/A
• Net Income: $58.23 million
• Net Margins: 23.86%
• Pretax Margin: 17.49%
• Return on Equity: 26.21%
• Return on Assets: 18.15%

Debt

• Debt-to-Equity Ratio: 0.10
• Current Ratio: 4.10
• Quick Ratio: 3.53

Sales & Book Value

• Annual Sales: $321.48 million
• Price / Sales: 3.65
• Cash Flow: $0.19 per share
• Price / Cash Flow: 41.75
• Book Value: $0.98 per share
• Price / Book: 8.14

Miscellaneous

• Outstanding Shares: 146,950,000
• Free Float: 145,036,000
• Market Cap: $1.17 billion
• Optionable: Optionable
• Beta: 1.94